Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
IPO Year: 2021
Exchange: NASDAQ
Website: absci.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/22/2025 | $9.00 | Buy | Needham |
10/2/2024 | $10.00 | Buy | Guggenheim |
7/3/2024 | $7.00 | Overweight | Morgan Stanley |
3/14/2024 | $13.00 | Sector Outperform | Scotiabank |
12/5/2023 | $3.00 | Overweight | KeyBanc Capital Markets |
5/4/2023 | $4.00 | Buy | H.C. Wainwright |
8/12/2022 | Overweight → Underweight | JP Morgan | |
7/18/2022 | $8.00 | Buy | Truist |
3/2/2022 | Market Perform | Cowen | |
2/1/2022 | $28.00 | Buy | Berenberg |
4 - Absci Corp (0001672688) (Issuer)
VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will be participating in the following upcoming investor conferences. Jefferies Global Healthcare Conference (New York, NY)Presentation on Thursday, June 5 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time Goldman Sachs 46th Annual Global Healthcare Conference (Miami, FL)Presentation on Monday, June 9 at 8:40 a.m. Eastern Time / 5:40 a.m. Pacific Time TD Cowen 4th Annual Tools/Dx Revolution (Dana Point, CA)June 22-25; Interested parties may contact their TD Cow
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the qu
Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and convenience over first-generation anti-TL1As Interim data anticipated in the second half of 2025 VANCOUVER, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled Phase 1 study evaluating ABS-101, an investigational anti-TL1A antibody engineer
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time 24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time Interested parties may access live and archived webcasts of the fireside chat sessions on the company's
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available fo
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company granted a non-statutory stock option to purchase an aggregate of 162,800 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the "Inducement Plan"), and is being made as an inducement material to the new employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option award h
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. Absci management is scheduled to participate in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company's investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients,
VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming TD Cowen 45th Annual Health Care Conference in Boston, MA. Absci management is scheduled to participate in a fireside chat on Monday, March 3rd at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company's investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for pati
8-K - Absci Corp (0001672688) (Filer)
SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)
SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)
10-Q - Absci Corp (0001672688) (Filer)
8-K - Absci Corp (0001672688) (Filer)
SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)
SCHEDULE 13D/A - Absci Corp (0001672688) (Subject)
DEFA14A - Absci Corp (0001672688) (Filer)
DEF 14A - Absci Corp (0001672688) (Filer)
8-K - Absci Corp (0001672688) (Filer)